How to Value a Multi-State Veterinary Group in 2026

Veterinary consolidation is the cleanest roll-up story in healthcare. The math is simple: companion animal spending has grown 7-9% annually for the past decade, 70% of US households own a pet, and the independent-practice market is still 60%+ unconsolidated. Layer on the COVID-era pet adoption boom and an aging pet population that requires more specialty care, and you get the single most aggressive PE and strategic acquisition environment in healthcare services.

Multi-state veterinary groups are trading at 11-14x EBITDA routinely, and top-tier specialty platforms are clearing 15-18x. I've watched this category go from a quiet sideshow to a $25 billion+ M&A market in under a decade. If you're building a multi-state vet group, you're in the best exit window I've seen in healthcare services.

The 2026 Multiple Framework

• Single hospital, $500K-$1M EBITDA: 6-9x. Corporate buyers pay a premium over associate buyers.
• 3-6 hospitals, single state, $2-4M EBITDA: 9-11x. Regional platforms compete.
• 6-15 hospitals, 2-3 states, $4-8M EBITDA: 10-12x. Mid-market platform candidate.
• 15-40 hospitals, 3-5 states, $8-20M EBITDA: 12-14x. Major platform acquisitions.
• Specialty/ER platforms, any size: 14-18x. Highest multiples in the category.

A $12M EBITDA three-state general practice group with 20 hospitals regularly closes at $135-$160M. Add a meaningful specialty and emergency component and that same EBITDA can clear $180M+. Specialty is the multiplier, and understanding why is the key to planning a premium exit.

For broader context, see our business valuation multiples by industry breakdown across healthcare.

Why Specialty and ER Trade at a Massive Premium

General practice veterinary is a solid business — recurring wellness visits, dental cleanings, vaccines, preventive care. Gross margins run 55-65%, EBITDA margins 16-22%, and the customer lifetime value on a well-bonded client is $4,000-$8,000. Buyers will pay 10-12x for that.

Specialty and emergency veterinary is a different animal entirely. A referral-based specialty hospital doing oncology, cardiology, neurology, or surgery generates average tickets of $3,000-$15,000 per visit and EBITDA margins of 22-30%. ER hospitals generate even higher margins because they bill overnight and holiday surcharges. Specialty and ER also can't be easily replicated — you need board-certified specialists (DACVIM, DACVECC, DACVS), and there are only a few thousand in the entire country. That scarcity drives multiples to 15-18x.

The best multi-state groups I've valued blend both. A group with 20 general practices and 2-3 specialty or ER hospitals captures referral revenue internally instead of losing it to competitors, which boosts same-store growth by 300-500 basis points annually. Buyers pay for that integrated model.

Named Acquirers in Veterinary

The buyer universe in vet is unusually concentrated — a handful of players control most of the deal flow, which is great news for sellers because they compete intensely for quality platforms.

• Mars Veterinary Health — the 800-pound gorilla. Owns Banfield (1,000+ hospitals), BluePearl (100+ specialty and ER hospitals), VCA (1,000+ hospitals), and Linnaeus. Mars is the most aggressive strategic acquirer and typically pays the highest multiples for platform fit.
• NVA (National Veterinary Associates) (TSG Consumer Partners, JAB Holding) — 1,400+ hospitals across general practice, specialty, and ER. Very active acquirer.
• Pathway Vet Alliance (TSG, Morgan Stanley Capital Partners) — 400+ hospitals, mid-market platform builder.
• PetVet Care Centers (KKR) — 450+ hospitals, active in the mid-market.
• Southern Veterinary Partners (Shore Capital, Jordan Company) — Southeast focused, rapidly expanding.
• CityVet, Thrive Pet Healthcare (TSG), Alliance Animal Health (Morgan Stanley Capital Partners), and Vetcor — mid-market consolidators active in the $3-15M EBITDA range.
• Ethos Veterinary Health (Sound Point Capital, formerly Brown Brothers Harriman) — specialty and ER focused, premium multiples.

Mars in particular has set the price floor in the category since acquiring VCA for $9.1 billion in 2017 and BluePearl in 2015. They can underwrite synergies unavailable to financial buyers (pharmacy, food, diagnostics integration with their broader pet care empire), which lets them bid 1-2 turns above financial buyers on strategic fit.

Multi-State Regulatory Variation

Veterinary medicine is regulated at the state level, and rules vary in ways that matter for multi-state operators.

Corporate practice restrictions. Some states prohibit non-veterinarian ownership of veterinary practices, which forces the same MSO structure used in dental DSOs. Texas, California, and New York have the most restrictive regimes and require a licensed veterinarian to hold legal ownership of the clinical entity while the MSO provides non-clinical services. Other states (Florida, Colorado, Arizona) are more permissive. Buyers will want to see clean MSO documentation in restrictive states and proper veterinarian-nominee structures.

DEA and controlled substance compliance. Every hospital needs an active DEA registration, and each veterinarian prescribing controlled substances needs individual DEA numbers. Multi-state groups face a compliance matrix that buyers will audit exhaustively. Any gaps in controlled substance logs are serious diligence findings.

State veterinary board rules on technician scope. What a credentialed veterinary technician can do varies significantly by state. This matters for operating leverage — states that allow technicians to perform dental prophylaxis, anesthesia induction, and minor procedures have meaningfully higher margin structures than states where everything must be vet-performed. A multi-state group operating in permissive states has better unit economics.

Veterinary telemedicine rules. Still evolving. Some states allow vet telehealth with an established veterinarian-client-patient relationship (VCPR); others don't. Groups with telemedicine infrastructure have optionality that buyers value, but the regulatory patchwork limits its current revenue impact.

What Drives Vet Group Multiples Up or Down

Same-store revenue growth. Buyers want to see 6%+ same-store growth, driven by a blend of price increases (3-4%), visit frequency (1-2%), and average ticket expansion through specialty capture (1-2%). Groups with flat or declining same-store trends get discounted hard.

Doctor productivity and retention. Veterinarian turnover is the single biggest operational challenge in the industry. A group that retains doctors at 90%+ annually is worth a full turn more than one running at 75% retention. Buyers will audit your associate comp structure, benefits, and culture indicators.

Wellness plan penetration. Subscription wellness plans (like Banfield's Optimum Wellness Plans) convert one-time transactional visits into recurring revenue. Groups with 20%+ wellness plan penetration are valued materially higher.

Real estate ownership. Owning the real estate beneath your hospitals creates valuation optionality — you can either sell the real estate separately to a net-lease REIT (Four Corners, STORE Capital, etc.) at 6-7% cap rates, or include it with the operating business at a blended multiple. Smart sellers structure this to their advantage.

Equipment and diagnostic capacity. In-house labs, digital radiography, ultrasound, CT, and MRI all drive revenue per visit up. A group with advanced diagnostic infrastructure captures more revenue per patient and is valued accordingly.

Deal Structure in Vet Transactions

Like DSO deals, vet platform transactions involve more than just the headline multiple.

Rollover equity of 20-40% is standard. The founder vet remains invested alongside the platform sponsor through the next hold period. Mars deals typically have less rollover because Mars is strategic; PE-backed platform deals typically have more.

Employment agreements of 3-5 years at market comp are standard for founding veterinarians, with non-competes extending 2-4 years post-employment.

Earnout contingent on same-store growth targets is common in mid-market deals. These are negotiable — push to minimize earnout exposure and maximize closing cash.

How to Prepare for a Multi-State Vet Exit

Build middle management. Regional medical directors, regional operations managers, and a central services team. Buyers pay a premium for intact infrastructure.

Add specialty or ER capacity. Even a single specialty hospital in your portfolio can lift the blended multiple by 1-2 turns. It captures referral revenue and signals platform sophistication.

Standardize your PIMS. Running some hospitals on AVImark, others on Cornerstone, and others on ezyVet is a value killer. Migrate to one system, ideally a cloud-based PIMS (ezyVet, Shepherd, Digitail) that buyers recognize as modern.

Get audited financials for the last three years and a sell-side Quality of Earnings from a reputable firm. At $100M+ valuations, buyers expect institutional-quality financials.

Address doctor retention proactively. Doctor comp is rising industry-wide. Better to raise comp 18 months before sale and grow EBITDA into it than to have buyers discount you for retention risk. For the full preparation framework, see how to prepare your business for sale.

The Bottom Line

Veterinary is the best exit environment in healthcare services right now. Buyers are deep, competitive, and paying double-digit multiples routinely. But the best outcomes go to founders who build genuine platforms — with specialty capacity, doctor retention, clean regulatory compliance across every state, and institutional financials — rather than just accumulating hospitals. The 14-18x multiples at the top of the market are reserved for operators who've done the work to look like a platform, not a collection.